Momelotinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MOMELOTINIB |
|---|---|
| Type | Drug |
| Aliases | OjjaaraOmjjaraМомелотиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PMF |
| Sources | SRC-COMFORT-I-VERSTOVSEK-2012 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | JAK1/JAK2 + ACVR1 inhibitor |
|---|---|
| Mechanism | JAK1/JAK2 inhibitor with additional ACVR1 inhibition that lowers hepcidin → improves anemia. Distinguishes momelotinib from ruxolitinib (which often worsens anemia). 2L for MF with anemia. |
| Typical dosing | MF: 200 mg PO once daily with or without food. Renal/hepatic dose adjustments apply. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Approved for MF with anemia (Hb <10) — MOMENTUM trial: spleen response + symptom improvement + Hb improvement compared with danazol. NOT registered in Ukraine. HBV / TB screening required before initiation.
Used By
Regimens
REG-MOMELOTINIB-PMF- Momelotinib (Ojjaara) for MF with anemia